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women requires special considerations because of the risk of hor-
mone induced growth and rupture. To prevent these potential
lethal complications, pregnancy is either often discouraged or
the surgical resection of large adenomas is recommended. It
may be questioned whether it is justified to deny a young woman
a pregnancy, as the biological behaviour of hepatocellular ade-
noma may be less threatening than presumed. In this study we
establish the management of hepatocellular adenoma during
pregnancy based on our own experience and literature.
Methods: Twelve women with documented hepatocellular ade-
noma were closely monitored during a total of 17 pregnancies
between 2000 and 2009. Their files were reviewed.
Results: In four cases, hepatocellular adenomas grew during
pregnancy, requiring a Caesarean section in one patient (two
pregnancies) at 36 and 34 weeks because of an assumed high risk
of rupture. In one case radiofrequency ablation therapy was
applied in the first trimester to treat a hormone sensitive hepato-
cellular adenoma, thereby excluding potential growth later in
pregnancy. No intervention was performed in the other 14 cases
and all pregnancies had an uneventful course with a successful
maternal and fetal outcome.
Conclusions: A ‘‘wait and see’’ management may be advocated in
pregnant women presenting with a hepatocellular adenoma. In
women with large tumours or in whom hepatocellular adenoma
had complicated previous pregnancies, surgical resection may be
recommended. In women with smaller adenomas it may no
longer be necessary to discourage pregnancy.
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j.jhep.2010.07.022Hepatocellular adenoma (HCA) is an uncommon benign tumour
of the liver that occurs particularly in women during their repro-
ductive years. The annual incidence rate of HCA is approximately
1–1.3 per 1,000,000 in women who have never used oral contra-
ceptives (OC), compared to 30–40 per million in long-term users
[1,2]. Thus, most HCA’s are associated with the use of OC [3–5],
an association which was first described in 1973 [3]. Other con-
ditions associated with the presence of HCA have been described,
including anabolic steroids, glycogen storage disease I and III and
pregnancy [6–13]. Most likely the association of HCA and preg-
nancy is due to the increased levels of steroid hormones
[14,15]. The presence of HCA can be complicated by hormone
induced growth and subsequently, spontaneous haemorrhagic
rupture that may threaten the life of both mother and child.
A growing or bleeding adenoma may present with persistent
or acute severe pain localized in the upper right quadrant and in
the epigastric region. Its presentation can be difficult to differen-
tiate from more common aetiologies of abdominal pain in preg-
nancy, like preeclampsia, Haemolysis Elevated Liver enzymes
and Low Platelets (HELLP) syndrome or non-obstetric pathology
like appendicitis, gallbladder disease, biliary pancreatitis, or pul-
monary embolism [16]. This differential diagnosis may lead to a
diagnostic delay. Early detection of HCA and a correct manage-
ment of these patients are highly important, since several manu-
scripts documented high maternal and fetal risks in case of a
ruptured HCA during pregnancy with a reported maternal and
fetal mortality rate of 44% and 38%, respectively [17]. In the last
decennium, the introduction and widespread use of highly
advanced image modalities have probably decreased the doctors’
delay in the diagnosis of HCA and the associated maternal and
fetal mortality risk might be reduced significantly. No ruptures
associated with gestation were reported in tumours less than
6.5 cm in size [17]. In non pregnant women haemorrhage has
been documented in a tumour of 4.5 cm in size but is most com-
monly seen in tumours greater than 10 cm [17]. The risk of rup-
ture is highest during the third trimester, most likely due to the
cumulating level of estrogens and an increase in hyperdynamic
circulation combined with an increase in vascularity of the liver
with growth of the adenoma [17]. In the postpartum period, the
risk of bleeding seems to be high as well; this can be explained
by the sudden withdrawal of estrogens after delivery that may
cause a sudden massive regression of the tumour leading to
haemorrhage [17]. Because of the unpredictable behaviour of10 vol. xxx j xxx–xxx
ocellular adenoma during pregnancy. J Hepatol (2010), doi:10.1016/
Table 1. Patient characteristics, diagnosis and management.
Case 
no. 
Age Presentation before 
pregnancy 
OC Diagnosis Management before Course of HCA after 
discontinuation OC 
,gnideelb(citamotpmyS921
haemodynamically stable) 
Yes 3 HCA’s, all <5.0 cm Elective surgery; 
segment 2/3 resection. 
Discontinuation OC
No regression 
lesions
latnedicni;stnialpmocoN732
finding on US 
Yes 1 HCA, <5.0 cm  Conservative.  Regression of lesion 
,gnideelb(citamotpmyS033
haemodynamically stable) 
Yes Multiple HCA’s, one >5.0 cm Conservative.  Unknown; stopped OC 
before HCA was 
;stnialpmoccificepsnU824
incidental finding on US 
Yes Multiple HCA’s, all <5.0 cm Conservative.  
Weight reduction 
Regression of lesions
;stnialpmoccificepsnU525
incidental finding on US 
Yes 3 lesions, atypical FNH/ 
adenoma, all <5.0 cm   
Conservative.  Unknown 
latnedicni;stnialpmocoN146
finding on US 
Yes 3 HCA’s, one >5.0 cm Elective surgery,  No regression or
growth of lesions
gnirudnoitatneserP337
pregnancy; symptomatic 
(pain right flank) 
Yes 1 HCA, <5.0 cm Before 2nd pregnancy RFA;
.a4tnemges
Discontinuation OC
Unknown; stop of OC 
HCA was diagnosed
stnialpmoccificepsnU328
(abdominal pain); 
diagnosis elsewhere
Yes 2 HCA’s, one >5.0 cm Elective embolisation.
Discontinuation OC
Growth of lesions
;stnialpmoccificepsnU139
incidental findings on US 
No Multiple HCA’s, one >5.0 cm Conservative. - 
,gnideelb(citamotpmyS5301
haemodynamically stable) 
Yes Multiple HCA’s, all <5.0 cm Elective surgery; 
resection.
Discontinuation OC
No regression or
 growth of lesions
;stnialpmoccificepsnU6311
incidental findings on CT 
Yes 1 HCA, <5.0 cm Conservative.  Regression of lesion
;stnialpmoccificepsnU8221
incidental findings on US 
Yes 2 HCA’s, one >5.0 cm Conservative.  Regression of lesions 
or growth of 
before 
diagnosed 
Discontinuation OC
Discontinuation OC
Discontinuation OC
Discontinuation OC
Discontinuation OC
Discontinuation OC
segment 4 resection
segment 3/6 
pregnancy
laparoscopic 
US = ultrasound.
Research ArticleHCA and highmaternal and fetal mortality of a ruptured HCA dur-
ing pregnancy women with a large HCA or a growing and hor-
mone sensitive HCA are advised to avoid pregnancy by most
experts (either incidental findings previous to a pregnancy or
women who experienced complications of an adenoma during
pregnancy) [2,15]. In addition, pregnancy itself limits the diagnos-
tic modalities and interventions may be associated with greater
risks in case of large adenomas [17].
At our centre, HCA’s with a diameter of 5 cm or larger that do
not show adequate regression after discontinuation of the use of
OC are considered for invasive treatment before pregnancy [15].
We were able to study 12 patients from a prospectively acquiredPlease cite this article in press as: Noels JE et al. Management of hepat
j.jhep.2010.07.022
2 Journal of Hepatology 201database who sustained HCA’s of different sizes during a total
number of 17 pregnancies.Patients and methods
The Erasmus Medical Centre is a tertiary referral centre for focal liver lesions with
an area of adherence of approximately 4 million people. From 2000 to 2009 all
data of patients with HCA were recorded prospectively in a weekly multidisci-
plinary meeting attended by a radiologist, hepatologist, pathologist, and surgeon
specialized in solid liver tumours. At the time of diagnosis every HCA patient was
advised to discontinue the use of OC and to prevent pregnancy. If pregnancy
would nevertheless occur, patients were strongly advised to contact our centreocellular adenoma during pregnancy. J Hepatol (2010), doi:10.1016/
0 vol. xxx j xxx–xxx
Table 2. Details of HCA with concern to pregnancy and follow-up after delivery.
Case 
.on
Pregnancy 
no.  
Growth  Interventions during 
pregnancy 
Follow-up after delivery Course of HCA’s during follow-up 
11 No None Follow-up elsewhere 
12 No None 10 months Regression, HCA hardly visible on last US 
2 No None 8 months Regression of lesion 
13 Yes: >5 cm C-section and 
administration on IC-
unit after delivery. 
17 months Some regression of 3 HCA’s, 
remaining HCA’s status quo. 
.erutpurfoecnediveoN
2 Yes: >5 cm, in 
two tumours 
C-section Ongoing  Some regression of HCA’s on CT,
No evidence of rupture 
14 No None None Unknown  
15 enoNmc5<tub,seY 24 months Regression of lesion 
2 No None Ongoing Unknown 
16 No None 3 months On US no evidence of focal liver lesions 
17 Yes: >5 cm None Follow up elsewhere Regression of lesion 
2 No: no tumour 
after RFA 
None 5 months On US no evidence of focal liver 
lesion 
18 No None 10  months 1 HCA regression, 1 HCA status quo ante 
2 No  None Ongoing Unknown 
19 No RFA 1st trimester; 
segment 6 
48 months 1 HCA regression after RFA, 
remaining HCA’s status quo ante 
101 2nd trimester 
minimal 
regression 
C-section 16 months Regression, HCA hardly visible on last 
MRI 
1*11 Unknown None 8 months Regression of lesion 
121 No None Ongoing  Unknown 
US = ultrasound.
*In case No. 11 there was no monitoring of HCA in our hospital.
JOURNAL OF HEPATOLOGYto evaluate growth of the tumour by the surgeon or hepatologist. Follow-up of the
fetus was carried out by the gynaecologist on a regular basis. A gynaecologist was
consulted only in those cases where a significant growth of the adenoma was
observed and its management could influence pregnancy.
The patients described (12 of 183 patients with HCA) were diagnosed by con-
trast enhanced CT or MR imaging between January 2000 and December 2009.
Until 2008 Gadolinium was the contrast agent of choice for MR imaging. In some
cases, Gadolinium was followed by Resovist contrast for increased diagnostic cer-
tainty. After 2008, MultiHance was the contrast agent of choice for MR imaging.
During their pregnancy they were closely monitored by means of repetitive
ultrasound and/or MR imaging. The frequencies of the measurements had no
fixed time schedule and depend on the size and changes in the characteristics
of the lesion. Their files were reviewed to evaluate presentation and time of pre-
sentation, use of OC, size and growth before and during pregnancy and postpar-
tum, complications and management during pregnancy, gestation time and way
of delivery, maternal and fetal outcome, and complications and management
after delivery.Results
Nearly all women (11 of 12) were diagnosed with HCA prior to
their pregnancy. In one patient, HCA was diagnosed during
pregnancy (Table 1). Eleven patients were using OC at the time
of diagnosis, or had used OC in the past. In four patients there
had been a regression of HCA’s after discontinuation of OC.
One patient became pregnant before it was possible to evaluatePlease cite this article in press as: Noels JE et al. Management of hepat
j.jhep.2010.07.022
Journal of Hepatology 201her hormone sensitivity for the HCA. Another two patients
stopped OC before HCA was diagnosed. In one patient there
was growth of the HCA two and a half years after discontinua-
tion of OC. No regression or growth of the HCA was noticed in
three patients. Ten patients presented in the first trimester of
pregnancy for monitoring of the HCA (Table 2). In one patient
with multiple HCA’s (case No. 3) there was serious concern
about the risk of rupture of these lesions. One year before preg-
nancy she presented with an acute sensation of upper right
quadrant pain, based on an intracapsular haemorrhage of an
HCA. She withdrew from medical attention during the first tri-
mester of her first pregnancy, but presented at the gynaecolo-
gist at 33 weeks gestation because of diabetes gravidarum.
Until then, the patient was under surveillance at her general
practitioner. At 33 weeks gestation, MR imaging, after ultra-
sound was performed, revealed a significant growth of the larg-
est lesion from 32 to 75 mm (Fig. 1). Another lesion showed
signs of haemorrhage that had been noticed 2 years ago. At that
time the lesion was measured 60 mm. This lesion measured
40 mm during her 33 weeks of gestation. To exclude any further
risks, it was decided to deliver the child by means of a Caesar-
ean section at 36 weeks with close postpartum monitoring of
the mother at the Intensive Care Unit for several days because
of an increased risk of haemorrhage. Despite our advice toocellular adenoma during pregnancy. J Hepatol (2010), doi:10.1016/
0 vol. xxx j xxx–xxx 3
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Fig. 1. MR-images of one of the adenomas (segment 2/3) of patient No. 3, nine
months after diagnosis and discontinuation of OC’s and in the 34th week of
pregnancy. Due to pregnancy and the volume of the abdomen, the tumour was
displaced in segment 2 and 3 cranially. The tumour shows significant growth.
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Fig. 2. Growth of the largest adenoma during pregnancy.
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Fig. 3. Regression of the largest adenoma postpartum.
Research Articleprevent further pregnancies, this patient became pregnant a
second time. In between her first and second pregnancy, there
was a regression of the lesion from 75 to 40 mm demonstrated
by MR imaging. During her second pregnancy, marked growth
of the HCA’s was noticed again, resulting in a Caesarean section
at 33 weeks. Both children were born healthy. Two patients
(case Nos. 5 and 7) showed growth in association with preg-
nancy and regression of the tumour postpartum (Figs. 2 and
3). In one patient (case No. 9), who wanted to keep her preg-
nancy, the tumour was treated with radiofrequency ablation
(RFA) during the first trimester of her second pregnancy. The
HCA showed regression during her pregnancy from 43  35
mm to 27  19 mm.
Maternal and fetal outcomes were excellent in all cases and
none of the HCA’s resulted in complications during pregnancy
or after delivery.Please cite this article in press as: Noels JE et al. Management of hepat
j.jhep.2010.07.022
4 Journal of Hepatology 201Discussion
The diagnosis of HCA may severely impact the life of a young fer-
tile woman, in particular because of the overall agreed advice to
avoid pregnancy. Literature on the course of HCA during preg-
nancy and recommended management is scarce. Some authors
advocate that women with HCA should not get pregnant [2,15].
As to date we cannot identify precisely those at risk of complica-
tions. It is likely that only a small subgroup of patients may expe-
rience complications. We provide a small but unique series of
women who were monitored meticulously during pregnancy.
Most cases of HCA related to pregnancy described in the litera-
ture were presented during pregnancy or shortly postpartum.
From the international literature between 1966 and 2003, Cobey
et al. retrieved 26 cases of women presenting with HCA during
pregnancy or early postpartum and proposed an algorithm for
their diagnosis and management [17]. Presentation was acute
and often dramatic with rupture of the adenoma in 16 women,
and frequently with a delay in establishing the correct diagnosis,ocellular adenoma during pregnancy. J Hepatol (2010), doi:10.1016/
0 vol. xxx j xxx–xxx
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with high maternal and fetal mortality. An aggressive approach
towards resection of HCA was advocated, especially for those
greater than 5 cm, based upon the high maternal and fetal mor-
tality (44% and 38%, respectively) for women presenting with
HCA during pregnancy. Small adenomas were supposed to be
managed by observation [17].
We have previously reported that more than half of the HCA’s
are discovered after the patient has sustained at least one preg-
nancy [18]. None of these patients have reported problems dur-
ing their pregnancies. In the current small series, just one
patient presented with a tumour growth of real concern and that
demanded an invasive intervention during pregnancy. In addi-
tion, rupture or other complications of solitary or multiple HCA’s
did not occur during intensive follow-up.
Based on these data we believe that a plea for a less aggressive
surgical approach towards HCA in pregnant women may be jus-
tified. Especially in small tumours (<5 cm) we propose close mon-
itoring and we believe it can be safe to allow pregnancy.
However, in some women in whom the growth of the HCA is sub-
stantial there is reason for concern. Some authors suggest a Cae-
sarean section (C-section) for HCA given the tendency to rupture
at term [17]. In our study three C-sections (two patients) were
performed, without complications. In one case (No. 3) C-section
was performed in consultation with the patient because of
marked growth and an unknown risk of rupture of the HCA’s.
In the other patient (case No. 10) C-section was due to decelera-
tions on the cardiotocography. All other patients had a normal
delivery which was never complicated by the rupture of an
HCA. Therefore, in our opinion, patients with HCA may deliver
vaginally if there are no complicating factors, like perinatal
problems.
Prognostic factors on rupture and malignant degeneration
during pregnancy remain unknown until this moment. Women
with HCA’s must be informed about the possible risks before
pregnancy. The literature on the management of HCA’s during
pregnancy is scarce due to the low incidence of HCA’s in general
[2,15], and the low number of HCA’s detected during pregnancy
in particular. Growth of HCA in pregnant women requires special
considerations for contemplating and timing possible
interventions.
In the case an intervention is indicated, surgical resection as
well as a minimal invasive approach may be considered, espe-
cially in smaller lesions. An intervention is safest in the 2nd tri-
mester [14]. RFA is a minimally invasive technique, which is
widely used for the treatment of patients with primary and sec-
ondary malignant tumours especially when resection is not an
option. RFA is believed to be a relatively safe procedure in expe-
rienced hands with low mortality and morbidity [19–22]. In
2006, Fujita et al. reported a pregnant patient with a HCA that
was treated by RFA during her 18th gestational week [23]. In
our centre RFA is occasionally used as an alternative treatment
in women with HCA. A disadvantage of RFA is that after ablation
of the tumour there is no material for pathological analysis.
When there is any doubt about the diagnosis, especially about
the benign character of the tumour, the diagnosis should be con-
firmed first. If malignancy cannot be excluded, surgical resection
is preferred. Selective arterial embolization can be used both as
an elective treatment to reduce the size of the HCA as well as
the initial emergency treatment in case of active bleeding of
the HCA [24–26]. It is a minimal invasive and safe procedure
compared to laparotomy and complications are rare. There arePlease cite this article in press as: Noels JE et al. Management of hepat
j.jhep.2010.07.022
Journal of Hepatology 201no large patient series, and especially in pregnant women with
HCA there is little experience with the use of arterial emboliza-
tion, although some authors suggest that it is a safe and effective
treatment for HCA [27,28]. Since the risk of radiation exposure
[29,30] to the fetus is increased, especially before 26 weeks of
gestation, we feel that selective arterial embolization should only
be used as an emergency treatment when RFA or surgery are not
a favourable option, for instance for more centrally located
tumours that are hardly accessible for RFA.
In conclusion, based on our small but unique prospective ser-
ies we propose not to discourage all women with HCA’s from
pregnancy. We hypothesize that pregnancy may be allowed in
case of a known HCA under certain conditions such as size and
after discussing the risk–benefit ratio with the patient. Women
should be aware of the potential risks as an intervention may still
be indicated during pregnancy, especially if the lesion is accessi-
ble for limited surgical resection or a percutaneous RFA. Close
monitoring by liver ultrasound every 6 weeks may offer adequate
information for surveillance of the hepatic lesion. In women who
have large tumours or who have experienced complications of
HCA in previous pregnancies, a negative advice against pregnancy
is justified because of an increased risk of complications. In that
case, surgical resection should be recommended before preg-
nancy. HCA in pregnant women implies special considerations,
therefore, additional data from different centres for the risk of
hormone induced growth and rupture of the adenoma during
pregnancy are needed.Conflict of Interests
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